MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis

被引：16

作者：

Grimaldi, Luigi M. E.

Prosperini, Luca ^{[1
]}

Vitello, Gaetano

Borriello, Giovanna ^{[1
]}

Fubelli, Federica ^{[1
]}

Pozzilli, Carlo ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Multiple Sclerosis Ctr, S Andrea Hosp, Dept Neurol & Psychiat, I-00185 Rome, Italy

来源：

MULTIPLE SCLEROSIS JOURNAL | 2012年 / 18卷 / 09期

关键词：

natalizumab; multiple sclerosis; magnetic resonance imaging; CONTROLLED TRIAL; DISEASE-ACTIVITY; SAFETY;

D O I：

10.1177/1352458512439438

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The recommended natalizumab dosage is 300 mg every 4 weeks. We evaluated radiological activity at various times from the last natalizumab infusion by examining 386 magnetic resonance imaging (MRI) scans from 166 natalizumab-treated patients with relapsing-remitting MS. Of 113 scans performed > 4 weeks after last natalizumab infusion, 26 were active (i.e. had >= 1 contrast-enhancing lesions). Risk of radiological activity increased by 1.34 fold for each week of delay with respect to the recommended 4-week dosing interval, compared with schedule-adherent patients (p < 0.0001). Our data suggest that an increased MRI activity >= 7 weeks from the last infusion of natalizumab should be considered in cases of therapy discontinuation.

引用

页码：1337 / 1339

页数：3

共 10 条

[1] Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society [J].

Ghezzi, A. ;

Grimaldi, L. M. E. ;

Marrosu, M. G. ;

Pozzilli, C. ;

Comi, G. ;

Bertolotto, A. ;

Trojano, M. ;

Gallo, P. ;

Capra, R. ;

Centonze, D. ;

Millefiorini, E. ;

Sotgiu, S. ;

Morra, V. Brescia ;

Amato, M. P. ;

Lugaresi, A. ;

Mancardi, G. ;

Caputo, D. ;

Montanari, E. ;

Provinciali, L. ;

Durelli, L. ;

Bergamaschi, R. ;

Bellantonio, P. ;

Tola, M. R. ;

Cottone, S. ;

Savettieri, G. ;

Tedeschi, G. .

NEUROLOGICAL SCIENCES, 2011, 32 (02) :351-358

[2] Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study [J].

Havrdova, Eva ;

Galetta, Steven ;

Hutchinson, Michael ;

Stefoski, Dusan ;

Bates, David ;

Polman, Chris H. ;

O'Connor, Paul W. ;

Giovannoni, Gavin ;

Phillips, J. Theodore ;

Lublin, Fred D. ;

Pace, Amy ;

Kim, Richard ;

Hyde, Robert .

LANCET NEUROLOGY, 2009, 8 (03) :254-260

[3] Three years of experience: the Italian registry and safety data update [J].

Mancardi, G. L. ;

Tedeschi, G. ;

Amato, M. P. ;

D'Alessandro, R. ;

Drago, F. ;

Milanese, C. ;

Popoli, P. ;

Rossi, P. ;

Savettieri, G. ;

Tola, M. R. ;

Comi, G. ;

Pozzilli, C. ;

Bertolotto, A. ;

Marrosu, M. G. ;

Grimaldi, L. M. E. ;

Laroni, A. ;

Vanacore, N. ;

Covezzoli, A. ;

De Rosa, M. ;

Piccinni, C. ;

Montanaro, N. ;

Periotto, L. ;

Iommelli, R. ;

Tomino, C. ;

Provinciali, L. .

NEUROLOGICAL SCIENCES, 2011, 31 :S295-S297

[4] A controlled trial of natalizumab for relapsing multiple sclerosis. [J].

Miller, DH ;

Khan, OA ;

Sheremata, WA ;

Blumhardt, LD ;

Rice, GPA ;

Libonati, MA ;

Willmer-Hulme, AJ ;

Dalton, CM ;

Miszkiel, KA ;

O'Connor, PW .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (01) :15-23

[5] Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis [J].

O'Connor, P. W. ;

Goodman, A. ;

Kappos, L. ;

Lublin, F. D. ;

Miller, D. H. ;

Polman, C. ;

Rudick, R. A. ;

Aschenbach, W. ;

Lucas, N. .

NEUROLOGY, 2011, 76 (22) :1858-1865

[6] Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice [J].

Outteryck, Olivier ;

Ongagna, J. -C. ;

Zephir, H. ;

Fleury, M. -C. ;

Lacour, A. ;

Blanc, F. ;

Vermersch, P. ;

de Seze, J. .

JOURNAL OF NEUROLOGY, 2010, 257 (02) :207-211

[7] A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis [J].

Polman, CH ;

O'Connor, PW ;

Havrdova, E ;

Hutchinson, M ;

Kappos, L ;

Miller, DH ;

Phillips, JT ;

Lublin, FD ;

Giovannoni, G ;

Wajgt, A ;

Toal, M ;

Lynn, F ;

Panzara, MA ;

Sandrock, AW .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (09) :899-910

[8] Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri®) in inflammatory diseases [J].

Stueve, Olaf ;

Bennett, Jeffrey L. .

CNS DRUG REVIEWS, 2007, 13 (01) :79-95

[9] Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients [J].

Vellinga, M. M. ;

Castelijns, J. A. ;

Barkhof, F. ;

Uitdehaag, B. M. J. ;

Polman, C. H. .

NEUROLOGY, 2008, 70 (13) :1150-1151

[10] Natalizumab Dosage Suspension: Are We Helping or Hurting? [J].

West, Timothy W. ;

Cree, Bruce A. C. .

ANNALS OF NEUROLOGY, 2010, 68 (03) :395-399

← 1 →